<SEC-DOCUMENT>0001144204-18-054041.txt : 20181016
<SEC-HEADER>0001144204-18-054041.hdr.sgml : 20181016
<ACCEPTANCE-DATETIME>20181016164127
ACCESSION NUMBER:		0001144204-18-054041
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181016
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181016
DATE AS OF CHANGE:		20181016

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Precipio, Inc.
		CENTRAL INDEX KEY:			0001043961
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				911789357
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36439
		FILM NUMBER:		181124774

	BUSINESS ADDRESS:	
		STREET 1:		12325 EMMET ST
		CITY:			OMAHA
		STATE:			NE
		ZIP:			68164
		BUSINESS PHONE:		203 787 7888

	MAIL ADDRESS:	
		STREET 1:		4 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRANSGENOMIC INC
		DATE OF NAME CHANGE:	20000119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv504924_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION<BR>
WASHINGTON, D. C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B><BR>
<B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B><BR>
<B>SECURITIES EXCHANGE ACT OF 1934 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
October 16, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>PRECIPIO,
INC.</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><I>(Exact Name of Registrant as Specified in Its Charter)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><I>(State of Incorporation)</I></FONT></TD>
    <TD STYLE="width: 2%; padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 32%; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>001-36439</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><I>(Commission File Number)</I></FONT></TD>
    <TD STYLE="width: 2%; padding: 0; text-align: center; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 32%; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>91-1789357</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><I>(I.R.S. Employer Identification No.)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>4 Science Park, New Haven, CT 06511</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Address of principal executive offices)
(Zip Code)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(203) 787-7888</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Registrant's telephone number, including
area code)</I></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B><BR>
<I>(Former name, former address and former fiscal year, if changed since last report date)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 23pt 0pt 0.35pt">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act
of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.35pt">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 8pt 0pt 0.35pt">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;<FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item 2.02</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results of Operations and financial Conditions</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On October 16, 2018, the Company issued
a press release announcing its preliminary, unaudited revenue for the third quarter of 2018. A copy of the press release issued
by the Company is furnished as Exhibit 99.1 to this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information in this Current Report on&nbsp;Form&nbsp;8-K&nbsp;furnished
under this Item&nbsp;2.02 including Exhibit 99.1 is furnished and shall not be deemed &ldquo;filed&rdquo; for any purpose, including
for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;),
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing
under the Exchange Act or under the Securities Act, regardless of any general incorporation language in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;9.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> &nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Exhibits.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.75in; border-bottom: black 1pt solid; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-size: 10pt"><B>No.</B></FONT></TD>
    <TD STYLE="width: 0.25in; text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding: 0; text-indent: 0"><A HREF="tv504924_ex99-1.htm" STYLE="-sec-extract: exhibit">99.1</A></TD>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="text-align: left; padding: 0; text-indent: 0"><A HREF="tv504924_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release dated October 16, 2018</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>PRECIPIO, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 5%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; padding: 0; text-indent: 0">/s/ Ilan Danieli</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">Ilan Danieli</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date:&nbsp;&nbsp;October 16, 2018&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv504924_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 65px; width: 333px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Precipio Announces Third Quarter 2018
Revenues Estimated to be 2.4 Times Third Quarter of 2017 Revenues</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Fourth consecutive Quarter of Triple-Digit
Year-over-Year Quarterly Revenue Growth; Year-to-Date Revenues Increased 163% over First Three Quarters of 2017</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>New Haven, CT, (October 16<SUP>th</SUP>, 2018) &ndash; </B>Specialty
cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced preliminary third quarter results representing continued triple
digit percentage year-over-year quarterly revenue growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On a preliminary basis, revenue for the third quarter of 2018
is expected to be approximately $648,000 versus $270,000 for the third quarter of 2017 - an increase of 140%. As a reminder, in
Q2-2018, Q1-2018, and Q4-2017, year-over-year revenue increases were 215%, 187% and 199%, respectively. Year-to date revenue for
the first three quarters of 2018 is estimated at $2.1M, a $1.3M increase over the $0.8M in revenue from the first three quarters
of 2017, representing a 163% increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pathology services, Precipio&rsquo;s core business, showed
quarter over quarter sequential growth of approximately 20%. These results were driven by the continued volume growth generated
by new client acquisitions. Management will review the drivers of pathology services in its upcoming shareholder conference call
following the SEC filing of Precipio&rsquo;s third quarter 2018 results. Management expects to file its quarterly results on or
before November 15<SUP>th</SUP>, 2018, and hold the call on November 19<SUP>th</SUP>, 2018. A future announcement will provide
detailed date and time for the Precipio Q3-2018 earnings conference call. We anticipate continued strong revenue growth throughout
the end of 2018 and into 2019, as the pathology services sales team matures and Precipio&rsquo;s regional sales coverage continues
to expand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Precipio&rsquo;s ICP market penetration plan remains focused
on launching additional kits to complement the product menu, in order to provide a broader offering to hospitals and laboratories
treating cancer patients. Precipio&rsquo;s R&amp;D team remains on track to release additional products throughout the end of
the year. This will result in a more robust offering for hospitals, large CRO&rsquo;s, OEM&rsquo;s and national scale labs, with
the goal of capturing a substantial share of the multi-billion dollar liquid biopsy market opportunity. The company continues
to advance partnerships with key industry players to bring ICP into the market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We expect a continued increase in pathology services
throughout the end of 2018 and into 2019. Sales of Precipio&rsquo;s pathology services continue to be the primary contributor
to the third quarter revenues, as the expanded sales team continues to perform well&rdquo;, said CEO Ilan Danieli. &ldquo;Through
rigorous training and goals-driven management, our team continues to successfully communicate the value proposition of academic
expertise and cancer pathology specialization in battling the problem of cancer misdiagnosis.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Precipio</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Precipio has built a platform designed to eradicate the problem
of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality
diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class academic institutions
specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine and Harvard&rsquo;s Dana-Farber
Cancer Institute, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information,
please visit www.precipiodx.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain statements in this press release constitute &ldquo;forward-looking
statements,&rdquo; within the meaning of federal securities laws, including statements related to ICP technology, including financial
projections related thereto and potential market opportunity, plans and prospects and other statements containing the words &ldquo;anticipate,&rdquo;
&ldquo;intend,&rdquo; &ldquo;may,&rdquo; &ldquo;plan,&rdquo; &ldquo;predict,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;could,&rdquo;
&ldquo;should,&rdquo; and similar expressions, constitute forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. The Company's actual results could differ materially from those anticipated in these forward-looking
statements as a result of various factors. Factors that could cause future results to materially differ from the recent results
or those projected in forward-looking statements include the known risks, uncertainties and other factors described in the Company&rsquo;s
definitive proxy statement filed on May 29, 2018, the Company&rsquo;s Quarterly Report on Form 10-Q for the quarter ended June
30, 2018 and on the Annual Report on Form 10-K for the year ended December 31, 2017 as well as the Company&rsquo;s prior filings
and from time to time in the Company&rsquo;s subsequent filings with the Securities and Exchange Commission. Any change in such
factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred
to in such statements. All information in this press release is as of the date of the release and the Company does not undertake
any duty to update this information, including any forward-looking statements, unless required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>investors@precipiodx.com</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #1155CC">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>+1-203-787-7888</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" !! 4T# 2(  A$! Q$!_\0
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MAS2!;"3SIW8R3S'K(YZGZ50UCQO%I6M2:9'IM]>3QHKM]G0-@']:ZBN.T_\
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MY?7LVHWLUW<',LS%F]O8>PKJPT&Y<QG4>E@L(6N-1M8E&6>9%'_?0KW6O*?
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9G2_<'TKL;G_D&Z;_ ->Z_P A116LQ1/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
